Uorfi Javed dissolves lip fillers: What to do if yours go wrong
Other frequent issues include:Uneven filler placementFiller migration (where the product moves from its intended spot)Using a filler that's not suited for lip augmentationSometimes, even high-quality fillers can go wrong if injected too superficially or too deep. 'Lip tissue is delicate and dynamic. It needs precise product placement, not a one-size-fits-all approach,' he adds.WHY IT HAPPENS: THE TECHNICAL SIDEDr Bhasin highlights that botched filler jobs often result from shortcuts and lack of planning. 'It's not just about injecting a product, it's about assessing the face holistically,' she says. 'Each face has unique proportions. Filler work must respect that.'Mistakes can happen if:The filler is of poor quality or unapproved.There is no clear treatment plan or facial mapping.HOW TO FIX A BOTCHED LIP FILLER JOBIf your lips look uneven, overfilled, or simply not how you expected, don't panic correction is possible. The first step is often to dissolve the filler using hyaluronidase, an enzyme that breaks down hyaluronic acid-based fillers.'We use hyaluronidase to safely melt the filler,' explains Dr Bhasin. 'But we always wait for the swelling to subside typically around two weeks before re-evaluating.'He warns against rushing into another filler appointment immediately. 'Overcorrecting right away can make things worse. Let your lips settle before making new decisions.'HOW LONG SHOULD YOU WAIT BEFORE FIXING IT?'Two weeks minimum,' says Dr Bhasin. 'The swelling and bruising need to subside completely before we can assess the true result.'If you're considering lip fillers, your best defense against a bad result is doing your homework. Dr Bhasin recommends checking:Medical credentials, choose only certified dermatologists or plastic surgeons.Experience with facial anatomy, lips are complex, dynamic structures.Before-after photos on official clinic platforms or verified social media.Transparency about the product, always ask the brand, batch number, and expiry date.Hygiene protocols, the procedure must be done in a sanitised, clinical setup.POST FILLERS MISTAKES THAT CAN RUIN YOUR RESULTadvertisementEven a well-done filler job can be compromised by poor aftercare. Dr Bhasin lists the most common mistakes:Massaging or pressing the lips unnecessarily.Intense exercise, sauna, or steam within the first 48 hours.Consuming alcohol or smoking post-procedure.Kissing too soon, yes, it can shift your filler.Skipping follow-ups with your injector.'Aftercare is 50% of the job,' she notes. 'Patients often ignore instructions and then blame the procedure.'CAN A BAD FILLER JOB CAUSE PERMANENT DAMAGE?Unfortunately, yes, though rare, the risks are real. Dr Bhasin warns: 'If injected into a blood vessel, filler can cause vascular occlusion cutting off blood supply to tissue. It's a medical emergency.'Other complications may include:ScarringLumps or nodulesLong-term asymmetry or lip distortion'This is why filler work is not a salon treatment, it's a medical procedure. It should only be done by qualified professionals,' she emphasises.HOW MUCH DOES CORRECTION COST?While fillers themselves may range from Rs15,000–Rs30,000, correction procedures like dissolving cost significantly less, around Rs 2,000 to Rs 5,000 per session. 'But it's not just about the money,' says Dr Bhasin. 'Your face is involved. You want peace of mind, not just affordability.'advertisementBefore concluding, Dr Bhasin made it clear that his observations are strictly professional and not directed at any individual.'I want to clarify that my comments are not aimed at any particular person,' he says. 'I'm only speaking from a medical perspective to help people understand what can go wrong with lip fillers and how to address it safely. Every case is unique, and no judgment is being passed.'Uorfi Javed's decision to dissolve her lip fillers is not just a celebrity headline, it's a reminder that cosmetic work, however common, carries risks if not done carefully. And while corrections are available, prevention is always better than cure.Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed medical professional or certified dermatologist before undergoing any cosmetic procedure, including lip fillers or correction treatments. Individual results and risks may vary. The opinions shared by the expert are intended to raise awareness and do not reflect a diagnosis or recommendation for any specific individual.- Ends
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
an hour ago
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.
Economic Times
an hour ago
- Economic Times
Blaming 'slow metabolism' for weight gain? Top doctor reveals muscle mass secret to reignite your body's fat-burning engine
iStock Dr. Sanjay Bhojraj challenges the notion of slow metabolism as the primary cause of weight gain, highlighting muscle loss as a more significant factor. After 30, muscle mass declines, reducing calorie burn. The Mayo Clinic supports this, stating muscle mass influences metabolic rate. (Image: iStock) For decades, 'slow metabolism' has been the go-to scapegoat for weight gain and failed diet attempts. From late-night infomercials to trendy wellness podcasts, fixing metabolism has been sold as the ultimate solution to slimming down. But is your metabolism truly the villain here? Dr. Sanjay Bhojraj, a US-based interventional cardiologist and certified functional medicine practitioner, is calling for a reality check. In a recent Instagram post that's gaining attention, he challenges the widely held belief that sluggish metabolism is the root cause of weight gain—and suggests we may be overlooking a much more fundamental issue: muscle loss. 'Muscle is your most metabolically active tissue,' Dr. Bhojraj wrote in the post. 'No muscle = no metabolic engine.' His claim is backed by compelling science. After the age of 30, we naturally lose 3–8% of muscle mass each decade, and that drop has serious consequences for how many calories we burn—even at rest. This muscle decline, combined with sedentary lifestyles and poor protein timing, can be a more significant factor in stubborn weight gain than metabolism itself. The doctor's blunt conclusion: 'We've blamed a slow metabolism for decades. But it's time we talked about muscle.' Supporting Dr. Bhojraj's assertion is a report by the Mayo Clinic, which confirms that basal metabolic rate (the energy your body uses at rest) is heavily influenced by body composition—particularly muscle mass. In other words, the more muscle you have, the more calories you burn even when you're not determinants of metabolic rate include: Body size and muscle mass – Larger bodies and more muscle mean higher calorie burn. Sex – Men usually have more muscle and less fat than women, resulting in faster metabolism. Age – Aging is linked to muscle loss, which slows down metabolism. Additionally, the Mayo Clinic states that weight gain usually stems from an imbalance between calories consumed and burned—not from inherently slow metabolism. Only rare medical conditions like hypothyroidism or Cushing syndrome significantly affect metabolic Bhojraj isn't alone in linking muscle loss with sluggish calorie burn. The Mayo Clinic explains that a drop in muscle mass naturally reduces your basal metabolic rate, meaning your body needs fewer calories than it once did. Yet, many people continue eating as though their bodies haven't changed—leading to gradual weight gain. And it's not just about building muscle at the gym. Everyday movement plays a huge role, too. Non-exercise activity thermogenesis (NEAT)—which includes walking around the house, fidgeting, or doing chores—can account for up to 800 calories burned per Bhojraj's prescription is simple yet powerful: Prioritize muscle. That means engaging in regular strength training and ensuring your diet includes enough protein, especially after age Mayo Clinic echoes this advice, recommending: Strength training at least twice a week for all major muscle groups. Aerobic activity for at least 30 minutes most days of the week. Staying active throughout the day—move often, not just during your workouts. Forget fad diets or unregulated supplements that promise a metabolic miracle. According to both experts, there's no substitute for building muscle and staying active if you want to maintain a healthy metabolism.
News18
2 hours ago
- News18
Dr Reddys profit rises marginally to Rs 1,410 cr in Jun qtr
New Delhi, Jul 23 (PTI) Dr Reddy's Laboratories on Wednesday reported a marginal increase in consolidated net profit to Rs 1,410 crore in the June quarter, aided by sustained growth in Europe and India. The Hyderabad-based drug major posted a net profit of Rs 1,392 crore in the year-ago period. Consolidated revenue rose 11 per cent to Rs 8,545 crore in the period under review from Rs 7,673 crore a year earlier. 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. 'We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. The company noted that growth during the quarter was broad-based, aided by contributions from the acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in the company's branded markets. In the North American market, its revenue declined by 11 per cent year-on-year to Rs 3,412 crore in the June quarter as compared with Rs 3,846 crore in the year-ago period. The decline was primarily due to increased price erosion in certain key products, including Lenalidomide, it stated. In Europe, the company reported a revenue of Rs 1,274 crore for the first quarter as compared with Rs 526 crore in the year-ago period. The growth in Europe was largely driven by revenues from the acquired NRT portfolio and incremental contributions from new product launches, though partly offset by price erosion, it stated. In India, revenue stood at Rs 1,471 crore against Rs 1,325 crore, a growth of 11 per cent year-on-year. Growth for the quarter was driven by introduction of new products, price increases and commercial execution, Dr Reddy's said. Shares of the company ended 0.58 per cent up at Rs 1,247.55 apiece on the BSE. PTI MSS MSS SHW view comments First Published: July 23, 2025, 18:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
